The INS News
No Result
View All Result
  • Home
  • News
    • Regional
    • Srinagar
    • Jammu
    • National
    • World
  • Business & Economy
  • Multimedia
    • Photo Gallery
    • Video Gallery
  • Health
  • Jobs & Careers
  • Press Releases
  • Blog
  • Home
  • News
    • Regional
    • Srinagar
    • Jammu
    • National
    • World
  • Business & Economy
  • Multimedia
    • Photo Gallery
    • Video Gallery
  • Health
  • Jobs & Careers
  • Press Releases
  • Blog
No Result
View All Result
The INS News
No Result
View All Result
Home News Regional

Influenza drug Molnupiravir reduces risk of death in Covid patients: DAK

INS Desk by INS Desk
December 29, 2021
A A
Vaccine must for recovered Covid-19 persons: DAK  ‘
Share on FacebookShare on TwitterWhatsappTelegramEmail

 

RELATED POSTS

Trumboo Cement Industries Launches Flagship Product ‘Solid Cement’ in Kashmir

Govt to re-open cases, return properties of terror-hit families in J&K: LG Sinha

Women-led development key to J&K’s peace, prosperity: LG Sinha

Srinagar, Dec 29: With the approval of influenza drug Molnupiravir for Covid-19 patients, Doctors Association Kashmir (DAK) on Wednesday said the drug reduces the risk of hospitalization and death in Covid patients.

“Molnupiravir prevents death in Covid patients when given early in the course of illness,” said DAK President and Influenza expert Dr Nisar ul Hassan.

Quoting a study, Dr Hassan said Molnupiravir reduced the risk of hospitalization and death from Covid by 30 percent.

“The drug was found to have life-saving benefits in mild to moderate cases of Covid-19 who were at risk of developing severe disease,” he said.

“The study also reported that Molnupiravir was equally effective against the Gamma, Delta and Mu variants as it was against the original strain,” he added.

The DAK President said while the drug was not tested against Omicron, early data suggests that the drug is effective against the new variant.

Buy JNews
ADVERTISEMENT

“Originally developed to treat influenza, Molnupiravir is a repurposed oral antiviral drug that works by blocking the virus from replicating in the body,” he said.

 Dr Nisar said the drug can safely be given to adults above 18 years of age.

“The drug is not recommended for use in children and pregnant women. It is not to be used for prevention of Covid or in patients hospitalized due to Covid,” he said.

“However, if it was initiated before hospitalization, it may be continued,” he added.

General Secretary DAK Dr Arshad Ali said Molnupiravir can be taken twice a day for five days by people at home.

“The pill has to be started as soon as possible, within five days of the start of symptoms,” he said.

“With the winter surge of Covid cases and the arrival of Omicron variant, the drug could provide a much needed arsenal to prevent Covid infection from culminating in severe disease,” he added.

Spokesperson DAK Dr Riyaz Ahmad Dagga said the antiviral drug has received approval in several countries like US and UK.

“Yesterday, India’s drug regulatory body cleared molnupiravir for the treatment of adult Covid-19 patients with mild to moderate disease and who have at least one risk factor for poor disease outcome,” he said.

“The risk factors that can put Covid patients at risk of severe disease include obesity, old age or underlying medical conditions like diabetes, heart, lung, kidney or liver disease, and cancer,” he added.

Previous Post

SIT Justifying Murder: PC On Hyderpora Killings

Next Post

2 Persons Gets 3 Years In Jail For Duping Man Of Rs 15.3 Lakhs Against MBBS Seat To His Son In 2005

INS Desk

INS Desk

Related Posts

Trumboo Cement Industries Launches Flagship Product ‘Solid Cement’ in Kashmir
Regional

Trumboo Cement Industries Launches Flagship Product ‘Solid Cement’ in Kashmir

July 13, 2025
Women-led development key to J&K’s peace, prosperity: LG Sinha
Regional

Govt to re-open cases, return properties of terror-hit families in J&K: LG Sinha

July 13, 2025
Women-led development key to J&K’s peace, prosperity: LG Sinha
Regional

Women-led development key to J&K’s peace, prosperity: LG Sinha

July 12, 2025
Govt suspends 12 J/KPDCL Engineers
Regional

Dy CM acts against poor road work; suspends JE, issues notice to Contractor

July 12, 2025
3 DCs among 41 IAS, JKAS officers transferred in J&K
Regional

7 IAS Officers transferred in J&K

July 12, 2025
Jal Shakti deptt ends adhocism, uncertainties, regularizes 1969 Engineers
Regional

Panel to optimize, consolidate treasuries

July 12, 2025
Next Post
Accused can’t be punished on moral conviction or suspicion: HC 

2 Persons Gets 3 Years In Jail For Duping Man Of Rs 15.3 Lakhs Against MBBS Seat To His Son In 2005

Hyderpora ‘Encounter’: SIT Says Investigation Still Underway, Warns Political Leaders Of ‘Penal’ Action

Hyderpora ‘Encounter’: SIT Says Investigation Still Underway, Warns Political Leaders Of ‘Penal’ Action

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *




Accused can’t be punished on moral conviction or suspicion: HC 

Marriage scheme for poor girls: HC orders action against fake beneficiaries

August 31, 2017
Forces Ransack Hurriyat Activist’s House in Anantnag, Locals  Protest

Forces Ransack Hurriyat Activist’s House in Anantnag, Locals Protest

January 18, 2019
Insulting Prophet Muhammad (SAW) not freedom of expression says European court

Insulting Prophet Muhammad (SAW) not freedom of expression says European court

October 26, 2018

About

Indian News Service (INS) is the first registered online news portal from the state of Jammu & Kashmir. Our creative team consists of like-minded and socially concerned team of media professionals who carry decades of experience in their field of profession at their back. Our core values have pillars in honesty, empathy, credibility, equality and integrity.

More

© 2022 INS News - Designed by GITS.

No Result
View All Result
  • Home
  • News
    • Regional
    • Srinagar
    • Jammu
    • National
    • World
  • Business & Economy
  • Multimedia
    • Photo Gallery
    • Video Gallery
  • Health
  • Jobs & Careers
  • Press Releases
  • Blog

© 2022 INS News - Designed by GITS.